STRENGTH IN NUMBERS

Strength in Numbers dedicated to my late mother Kay

Life-extending cancer drugs to be axed by NHS

NHS England de-lists costly Kadcyla drug, among 16 others, in wake of ‘overspent’ Cancer Drugs Fund

New and costly cancer drugs developed to extend the lives of patients are expected to be axed on Friday from an NHS list. Among the drugs NHS England is expected to “de-list” from the Cancer Drugs Fund is Kadcyla, which holds the record as the most expensive cancer drug brought to market, costing £90,000 annually per patient.

Kadcyla, made by Roche, was rejected from general NHS use by the National Institute for Health and Care Excellence (Nice), the body that assesses new medicines for their cost-effectiveness.

Nice agreed the drug was effective for women whose advanced breast cancer no longer responded to Herceptin, but its chief executive, Sir Andrew Dillon, was outspoken about the “unacceptable” price tag. “We had hoped that Roche would have recognised the challenge the NHS faces in managing the adoption of expensive new treatments by reducing the cost of Kadcyla to the NHS,” Dillon said in April 2014.

Click on the link to read more

http://www.theguardian.com/society/2015/sep/03/life-extending-cancer-drugs-to-be-axed-by-nhs

1447

Filed under: Cancer, NHS

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Pages

%d bloggers like this: